Towards personalizing treatment strategies in mCRPC: can dual-tracer PET-CT provide insights into tumor biology, guide the optimal treatment sequence, and individualize decision-making (between chemotherapy, second-generation anti-androgens and PSMA-directed radioligand therapy) early in the disease course?
PSMA-directed radioligand therapy) early in the disease course? The therapeutic armamentarium of mCRPC has witnessed rapid evolution over the recent years, with a gamut of newly approved and "on-trial under clinical evaluation" therapies added to the traditional therapies including the cytotoxic che...
| Publicado en: | European Journal of Nuclear Medicine & Molecular Imaging Vol. 47; no. 8; pp. 1793 - 1798 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Jul2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |